RHY 1.64% 6.2¢ rhythm biosciences limited

New York Times article

  1. 4,330 Posts.
    lightbulb Created with Sketch. 2623
    There is a New York Times article today, 14 January, praising the advantages of the faecal test compared to colonoscopies. No mention of ColoSTAT or Rhythm but does mention Cologuard as an inferior test. One advantage they say FIT has is that it costs around US$20 compared to a colonoscopy costing about US$1,000. The other is that unless you produce a positive FIT test you do not need to leave home and go visit doctors and hospitals (a big plus in the US at the moment).

    Someone the other day on hc reckoned that FIT costs over A$100 a test and it seems that anything medical usually costs much more in the US than here. So either the poster or the NYT was a bit off in their cost estimate.

    Another interesting point is that given the combination of colon cancer testing plummeting this year in the US and the probability that the US authorities will drop the starting age for testing from 50 to 45 they expect that there will at some point in the near future a massive overdemand for testing. Could be perfect timing for ColoSTAT to go commercial.

    I have not provided a link to the article as it is behind a paywall (though just sign up and you get limited access). The online article is "A Colonoscopy Alternative Comes Home". Final point, it really avoids addressing the fact that FIT requires you to play with your sh!t: a real snow job.
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
(20min delay)
Last
6.2¢
Change
0.001(1.64%)
Mkt cap ! $15.41M
Open High Low Value Volume
6.1¢ 6.2¢ 6.1¢ $1.668K 26.97K

Buyers (Bids)

No. Vol. Price($)
2 102393 6.1¢
 

Sellers (Offers)

Price($) Vol. No.
6.2¢ 144960 1
View Market Depth
Last trade - 15.42pm 05/07/2024 (20 minute delay) ?
RHY (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.